Cellular therapy: a key part of EBMT 2017
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
Challenges with measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
What are the alternative treatment options for relapsed or elderly AML patients?
Myeloma 2016: Panel discussion on novel treatments
Keith Stewart et al.